Zhong Guo Xin Wen Wang·2025-08-29 08:35Core Viewpoint - The "Lai Fu Initiative" was launched by Kexing Group and 70 other companies in the biopharmaceutical sector at the 2025 Supply Chain Ecological Conference, aiming to foster global cooperation in China's health industry and share market opportunities and development benefits [1] Group 1: Industry Trends - The biopharmaceutical industry is undergoing a transformative wave driven by innovation, reshaping the industry landscape and becoming a key force for economic growth and technological innovation [1] - The initiative emphasizes the need for collaborative research platforms to overcome key bottlenecks in drug and vaccine development, promoting shared technological achievements and accelerating product innovation cycles [1] Group 2: Market Opportunities - Industry experts believe that the current uncertainties in the sector may conceal greater opportunities for growth [1] - Kexing Group's CEO highlighted that the integration of biotechnology and AI technology is reshaping health demands and unlocking significant growth opportunities, with China leveraging its 1.4 billion domestic market to establish a global strategy in biotechnology [1]